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SurvivalObjective. Cervical cancer with ≤5 mm depth of invasion and N7 mm horizontal spread is classified FIGO IA
instead of FIGO IB in the revised staging system, as horizontal spread is no longer considered.We aimed to deter-
mine the incidence of lymph node metastasis (LNM) and, consequently, the necessity of pelvic lymph node as-
sessment.
Methods. Patients diagnosed between January 2015 and May 2019 with cervical cancer FIGO (2009) stage IB
with ≤5 mm depth of invasion and N7 mm horizontal spread, were identified from the Netherlands Cancer Reg-
istry. Associations between disease-characteristics and lymph nodemetastasis (LNM), and overall survival, were
assessed.
Results. Of 170 patients, six (3.5%) had LNM: 4/53 (7.6%) with adenocarcinoma and 2/117 (1.7%) with squa-
mous cell carcinoma (p= .077). Four-year overall survival was 98.2%. LNMwas observedmore often in tumours
with LVSI (4/43 patients, 9.3%) than without LVSI (2/117 patients, 1.7%) (p = .045). In adenocarcinoma with
3–5 mm depth of invasion LNM rate was 10% (4/40). None of the following tumours were observed with
LNM: squamous cell carcinoma without LVSI (0/74); adenocarcinoma with b3 mm depth of invasion (0/13);
b3 mm depth of invasion without LVSI (0/36).
Conclusions. Lymphnode assessment is essential in any tumourwith LVSI or in adenocarcinomawith 3–5mm
depth of invasion. It can be omitted in squamous cell carcinoma without LVSI, in adenocarcinoma with b3 mm
depth of invasion and in any tumours without LVSI and with b3 mm depth of invasion.
© 2020 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).& Development, Netherlands
wartier 419, 3511 DT Utrecht,
. This is an open access article under1. Introduction
In 2018, the International Federation of Gynaecology and Obstetrics
(FIGO) staging system for cervical cancer has been revised [1,2]. From
now on, horizontal spread is no longer considered in determining
FIGO stage for cervical cancer with ≤5 mm depth of invasion. One
major consequence is that patients with these tumours, withoutthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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be staged as FIGO IA instead of IB.
For FIGO (2009) stage IB, surgical treatment requires the addition of
pelvic lymphadenectomy, as the risk of lymph nodemetastasis (LNM) is
high (12.2%–29.8% [3–6]). In patients with stage IA the decision to per-
form a lymphadenectomy mainly depends on the presence of
lymphovascular space invasion (LVSI). The clinical significance of LVSI
in tumours with ≤5 mm depth of invasion has been a subject of debate
for decades [7]. Its presence might affect the treatment plan, even
though it has no role in the FIGO classification [2,8]. Gynaecologic oncol-
ogists might consider refraining from lymphadenectomy in patients
with stage IAI and stage IA2 without LVSI, because of the low risk of
LNM (0.1% and 1.3%, respectively), avoiding overtreatment and addi-
tional morbidity [7,9]. For patients with LVSI, lymphadenectomy is al-
ways recommended because of the high risk of LNM (12.0%) [9].
This study aimed to retrospectively evaluate the incidence of LNM in
tumourswith ≤5mmdepth of invasion and N7mmhorizontal spread, to
determinewhether they are likely to benefit frompelvic lymphnode as-
sessment. Moreover, the association between LVSI, histological subtype
and LNM is examined.
2. Methods
2.1. Study design and patient selection
A nationwide retrospective cohort study was performed by
analysing data from the Netherlands Cancer Registry (NCR), a
population-based registry with coverage of all newly diagnosed malig-
nancies in the Netherlands since 1989. The registration clerks routinely
extract patient information frommedical records within hospitals. They
all undergo the same extensive training, using one coding manual spe-
cifically developed for cervical cancer, creating uniformity in data inter-
pretation and entry. Data on vital status and date of death, obtained3803 patients were diagnosed 
between January 2015 – May 
2019 with cervical cancer 
3522 patients with 
adenocarcinoma or squamous 
cell carcinoma between 
January 2015 – May 2019
1201 patients with 2009 FIGO 
IB between January 2015 –
May 2019
2321 patients excluded due to 
other FIGO stage
1015 patients with missing or 
other values on depth of invasion 
or horizontal extension
281 patients excluded due to 
other histological subtype
Fig. 1. Patient selecfrom themunicipal demography registries, were available until January
2019.
All patients newly diagnosedwith FIGO (2009) IB cervical cancer be-
tween January 2015 and May 2019, were identified from the NCR. In-
cluded were adenocarcinoma or squamous cell carcinoma, with:
≤5 mm depth of invasion and N7 mm horizontal spread. Patients were
excluded if: no lymph nodes were examined; neoadjuvant chemo
(radio)therapywas administered; data on depth of invasion or horizon-
tal spread were missing. Data were collected by the registration clerks
on patient and disease-related characteristics (including age at diagno-
sis, FIGO stage, histological subtype, differentiation grade, depth of inva-
sion, LVSI, number of examined lymph nodes, number of positive lymph
nodes, primary treatment and all-cause mortality). Pathology speci-
mens were reviewed by a gynaecological pathologist.
2.2. Statistical analysis
Descriptive statistics were used to describe characteristics and the
presence of LNM. Associations between LNM and qualitative variables
were assessed using Fisher's exact test, whereas quantitative variables
were assessed by theMann–Whitney U test. The Kaplan–Meier method
was applied to calculate overall survival. All analyses were performed
using Stata/SE version 14.2 (Stata Corporation, College Station, TX,
USA). Statistical tests were two-tailed and considered significant at
p b .05.
3. Results
Of the 3803 patients diagnosed with cervical cancer between Janu-
ary 2015 and May 2019, 170 (4.5%) met the inclusion criteria (Fig. 1).
Patient and disease-related characteristics are presented in Table 1. Me-
dian age at diagnosis was 39 (range 26–76 years). After a median186 patients with ≤5 mm depth 
of invasion and >7 mm 
horizontal extension
172 patients with examined 
lymph nodes
14 patients without examined 
lymph nodes
2 patients with neoadjuvant 
treatment
170 patients, diagnosed 
between January 2015 –
May 2019 with FIGO IB 
cervical adenocarcinoma or 
squamous cell carcinoma 
with ≤5 mm depth of 
invasion and >7 mm 
horizontal extension, with 





Depth of invasion, histological subtypes and LVSIa, related to lymph node metastasis.
Characteristics, n (%) Total Depth of invasion (n = 170) Pb
b3 mm LNM, yes 3–5 mm LNM, yes
Histological subtype
SC 117 34 (29) 1 (3) 83 (71) 1 (1) 0.50
AC 53 13 (25) 0 (0) 40 (75) 4 (10) 0.56
LVSI
Yes 43 10 (23) 1 (10) 33 (77) 3 (9) 1.00
No 117 36 (31) 0 (0) 81 (69) 2 (2) 1.00
Characteristics, n (%) Total Histological subtype (n = 170) P
SC LNM, yes AC LNM, yes
Depth of invasion
b3 mm 47 34 (72) 1 (3) 13 (28) 0 (0) 1.00
3–5 mm 123 83 (67) 1 (1) 40 (33) 4 (10) 0.04
LVSI
Yes 43 35 (81) 2 (6) 8 (19) 2 (25) 0.15
No 117 74 (63) 0 (0) 43 (37) 2 (5) 0.13
Characteristics, n (%) Total LVSI (n = 160) P
LVSI, yes LNM, yes LVSI, no LNM, yes
Depth of invasion
b3 mm 46 10 (22) 1 (10) 36 (78) 0 (0) 0.22
3–5 mm 114 33 (29) 3 (9) 81 (71) 2 (2) 0.15
Histological subtype
SC 109 35 (32) 2 (6) 74 (68) 0 (0) 0.10
AC 51 8 (16) 2 (25) 43 (84) 2 (5) 0.11
SC squamous cell carcinoma; AC adenocarcinoma; LVSI lymphovascular space invasion;
LNM lymph node metastasis.
a Missing values LVSI 6%, n = 10.
b Fisher's exact test.
Table 1
Characteristics of 170 cervical cancer patients (2009 FIGO stage IB) with tumours with ≤5 mm depth of invasion and N7 mm horizontal extension, organised by presence of lymph node
metastasis.
Characteristics, n (%) Missing Full cohort
(N = 170)
LNM, no (n = 164;
96%)
LNM, yes (n = 6; 4%) Pa
Age, yearsb 39 (26–76) 39 (26–76) 35 (27–55) 0.55
Primary treatment 0.06
Surgery 161 (95) 156 (95) 5 (83)
Chemoradiation 1 [1] 0 (0) 1 (17)
Conisation 8 [5] 8 [5] 0 (0)
Histological subtype 0.08
Squamous cell carcinoma 117 (69) 115 (70) 2 (33)
Adenocarcinoma 53 (31) 49 (30) 4 (67)
Differentiation grade 48 (28) 0.33
1 17 (14) 16 (14) 1 (20)
2 63 (52) 62 (53) 1 (20)
3 42 (34) 39 (33) 3 (60)
Lymph nodes examinedb 22 (2–57) 22 (2–57) 19 (9–37) 0.32
Lymph nodes positiveb 0 (0–2) – 2 (1–2)
Depth of invasion 0.47
b3 mm 47 (28) 46 (28) 1 (17)
3–5 mm 123 (72) 118 (72) 5 (83)
Lymphovascular space invasion 10 [6] 43 (27) 39 (25) 4 (67) 0.05
Follow-up, monthsb 19 (0–49) 19 (0–49) 25 (10−30) 0.76
All-cause mortality 7 [4] 2 [1] 2 [1] 0 (0) 0.93
LNM lymph node metastasis. Because of rounding, percentages might not sum to 100%.
a Mann-Whitney U test for continuous variables, Fisher's exact test for categorical variables.
b Median (range).
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resulting in a 4-year overall survival rate of 98.2%.
Squamous cell carcinoma was the most prevalent histological sub-
type (68.8%) and most of the tumours had an invasion depth of
3–5 mm (72.4%). LVSI was confirmed in 26.9% of the tumours, with
higher rates in squamous cell carcinoma compared to adenocarcinoma
(32.1% vs. 15.7%, p = .035). The median number of examined lymph
nodes was 22, ranging from 2 to 57.
Six of the 170 patients (3.5%) had pathologically confirmed LNM.
Stratified by invasion depth, LNM was detected in 1/48 patients (2.1%)
with b3 mm depth of invasion and in 5/130 (3.9%) with 3–5 mm
depth of invasion (p = .49). Comparing histological subtypes, 4/53 pa-
tients (7.6%) with adenocarcinoma and 2/117 (1.7%) with squamous
cell carcinomawere observed with LNM (p= .08). LNMwas confirmed
in four of the patients with LVSI (9.3%), which was significantly more
often than in patients without LVSI (n = 2; 1.7%), p = .045.
Analyses on common histological subtypes, depth of invasion and
LVSI in relation to LNM, are shown in Table 2. A decision tree for
lymph node assessment, combining these characteristics, is presented
in Fig. 2. LNM was confirmed in 0/13 patients (0.0%) with b3 mm
depth of invasion and adenocarcinoma and 4/40 patients (10.0%) with
3–5 mm depth of invasion and adenocarcinoma (p = .56). None of
the 36 patients (0.0%) with b3 mm depth of invasion without LVSI,
had LNM. Of the patients with adenocarcinoma and LVSI, 2/8 (25.0%)
had LNM, next to 2/35 patients (5.7%) with squamous cell carcinoma
and LVSI (p = .15). None of the 74 patients (0.0%) with squamous cell
carcinoma without LVSI had LNM.
4. Discussion
Our results have important implications for the treatment of patients
with cervical cancerwith ≤5mmdepth of invasion and N7mmhorizon-
tal spread. We found the incidence of pathologically confirmed LNM,
and consequently the benefit of lymph node assessment, to be associ-
ated with LVSI and histological subtype.
A large retrospective study by Bean et al. [10] on oncological out-
come after stage IA cervical cancer, included 5749 patients with squa-
mous cell carcinoma and 1567 with adenocarcinoma. They found low
rates of LNM (b1.0%) in both histological subtypes and suggest that
these patients may not benefit from pelvic lymphadenectomy.However, the authors argue to take into account LVSI in this decision,
as its presence is associated with LNM – an association which has
been demonstrated previously [9,11,12]. In a review by van Meurs
et al. on 535 patients with stage IA2 cervical cancer [9], tumours with
LVSI were observed with a 12.0% LNM rate, versus 9.3% in our study.
LNM rates were markedly lower in those with LVSI (1.3%), similar to
our study (1.7%). Van Meurs et al. [9] reported an association between
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Fig. 2. Lymph node assessment decision tree. LVSI lymphovascular space invasion; AC adenocarcinoma; SC squamous cell carcinoma.
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tomy for tumours with squamous cell carcinoma (LNM rate 3.3%),
next to any tumour with LVSI. In our study, relatively high rates of
LNM were observed in adenocarcinoma (7.5%), especially in combina-
tion with LVSI (25.0%). In adenocarcinoma without LVSI, LNM was ob-
served in 4.7%. Moreover, all adenocarcinoma with LNM had 3–5 mm
depth of invasion. For squamous cell carcinoma, LNM was only associ-
ated with the presence of LVSI: 0.0% in tumours without LVSI and in
5.7% tumourswith LVSI. Although the sample size and number of events
hamper statistical testing to reach significance in our study, LNM seems
to be associated with LVSI and histological subtype in tumours with
≤5 mm depth of invasion and N7 mm horizontal spread.
Current guidelines recommend a pelvic lymphadenectomy in FIGO
IA cervical cancer to detect LNM, except for stage IA1 without LVSI.
The incidence rate of LNM in our study (3.5%) justifies the question
whether lymphadenectomy, with risk of significant morbidity, is advis-
able in stage IA tumours with N7mmhorizontal spread. Sentinel lymph
node detection has been proposed as alternative procedure, with less
morbidity, to identify LNM. A review by Tax et al. [13] on FIGO IA2, IB1
and IIA1 cervical cancer, reported the highest sensitivity and negative
predictive value in of patients with bilateral sentinel lymph node detec-
tion and without suspicious lymph nodes pre- and perioperatively. The
authors argued a residual risk of occult metastasis of 0.08% in this group,
corresponding to 1/1275 patients, sufficient to replace a full pelvic
lymphadenectomy by a sentinel lymph node procedure.
For stage IA without LVSI, a trend towards more conservative treat-
ment is discernible. Consequently, these patients may be treated by a
general gynaecologist, but only after being discussed in amultidisciplin-
ary team, including review by a specialised pathologist. As this is a part
of daily practice in the Netherlands, we deem it possible, but unlikely,
that patients in our cohort were undertreated.
The strength of this study is the use of the Netherlands Cancer Reg-
istry, providing a nationally representative sample of the Dutch popula-
tion, reflecting daily practice. Although a highly specific group of
patients was examined, a relatively large sample was included for anal-
ysis. Its limitation lies in the retrospective data collection, which heavily
relies on the quality of data in medical records and reports of pathology
laboratories. One major limitation lies in the number of events from
which our conclusions were derived. The limited number of patients
with LNM indicates that our study results require validation.
In conclusion, LNMwas detected in 3.5% of the patients with cervical
cancer with ≤5 mm depth of invasion and N7 mm horizontal spread.
Lymph node assessment is essential in any tumour with LVSI or in ade-
nocarcinoma with 3–5 mm depth of invasion. It can be omitted insquamous cell carcinoma without LVSI, in adenocarcinoma with
b3 mm depth of invasion and in any tumours without LVSI and with
b3 mm depth of invasion.
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